Self-assembled nanoparticles of poly(lactide)--Vitamin E TPGS copolymers for oral chemotherapy.

Nanoparticles (NPs) of poly(lactide)-Vitamin E TPGS (PLA-TPGS) copolymers were synthesized by a dialysis method in the present study to formulate paclitaxel for oral chemotherapy with Caco-2 cells as an in vitro model of the gastrointestinal (GI) drug barrier. The PLA-TPGS NPs were of size 340nm in diameter with 5.2% drug loading. The drug release kinetics showed a 31% initial burst in the first day, followed by 80% accumulative drug release after 30 days in the PBS buffer at pH 7.4, and the release rate was found lower in simulated gastric and intestinal conditions. The internalization of fluorescent PLA-TPGS NPs by Caco-2 cells was visualized by confocal laser scanning microscopy (CLSM). PLA-TPGS NPs showed significant increase in the cellular uptake by 1.8- and 1.4-fold in comparison with poly(lactide-co-glycolide) (PLGA) NPs cultured with HT-29 and Caco-2 cells, respectively, and the cellular uptake efficiency was found affected by the incubation time and the particle concentration in the culture medium. Investigation on HT-29 and Caco-2 cytotoxicity showed advantages of the PLA-TPGS NP formulation versus Taxol. The IC(50) of the PLA-TPGS NP formulation with HT-29 cells was found 40% lower than of Taxol at the same dose of paclitaxel. The results obtained in this research demonstrated feasibility for the PLA-TPGS NPs to be applied for oral delivery of paclitaxel as well as other anticancer drugs.

[1]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[2]  R. Sokol,et al.  Improvement of cyclosporin absorption in children after liver transplantation by means of water-soluble vitamin E , 1991, The Lancet.

[3]  Gérard Hopfgartner,et al.  P‐Glycoprotein and Surfactants: Effect on Intestinal Talinolol Absorption , 2005, Clinical pharmacology and therapeutics.

[4]  J. Nah,et al.  Clonazepam release from core-shell type nanoparticles of poly(ε-caprolactone)/poly(ethylene glycol)/poly(ε-caprolactone) triblock copolymers , 2000 .

[5]  S. Feng,et al.  Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[6]  L. Grochow,et al.  Phase I trial of taxol in patients with advanced cancer. , 1987, Cancer treatment reports.

[7]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Mizrahi,et al.  Use of water-soluble liquid vitamin E to enhance cyclosporine absorption in children after liver transplant. , 1993, Transplantation proceedings.

[9]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[10]  Shyr‐Yi Lin,et al.  Physical characterizations of microemulsion systems using tocopheryl polyethylene glycol 1000 succinate (TPGS) as a surfactant for the oral delivery of protein drugs. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[11]  Si-Shen Feng,et al.  Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. , 2006, Biomaterials.

[12]  Si-Shen Feng,et al.  Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. , 2004, Current medicinal chemistry.

[13]  J. Silverman,et al.  Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS) , 1999, Pharmaceutical Research.

[14]  Alberto Guenzi,et al.  Improvement of the Bioavailability of Colchicine in Rats by Co-administration of D-α-Tocopherol Polyethylene Glycol 1000 Succinate and a Polyethoxylated Derivative of 12-Hydroxy-Stearic Acid , 2002, Arzneimittelforschung.

[15]  J. Schellens,et al.  Oral Delivery of Taxanes , 2001, Investigational New Drugs.

[16]  Chi‐Chang Lin,et al.  Stability and Release Performance of a Series of Pegylated Copolymeric Micelles , 2003, Pharmaceutical Research.

[17]  D. Maysinger,et al.  Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles , 2003, Science.

[18]  Gordon L. Amidon,et al.  The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent , 1997, Pharmaceutical Research.

[19]  D. Maysinger,et al.  Cellular Internalization of Poly(ethylene oxide)-b-poly(ε-caprolactone) Diblock Copolymer Micelles , 2002 .

[20]  Si-Shen Feng,et al.  PLGA/TPGS Nanoparticles for Controlled Release of Paclitaxel: Effects of the Emulsifier and Drug Loading Ratio , 2003, Pharmaceutical Research.

[21]  Si-Shen Feng,et al.  Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. , 2005, Biomaterials.

[22]  James E Polli,et al.  Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[23]  D. Attwood,et al.  The influence of gastric acidity and taste masking agent on in situ gelling pectin formulations for oral sustained delivery of acetaminophen. , 2006, Biological & pharmaceutical bulletin.

[24]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Panchagnula.  Pharmaceutical aspects of paclitaxel , 1998 .

[26]  M. Varma,et al.  Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  V. Lenaerts,et al.  Tissue concentration of nanoencapsulated radio-labelled cyclosporin following peroral delivery in mice or ophthalmic application in rabbits , 1996 .

[28]  K. Skorecki,et al.  Reduced cyclosporin accumulation in multidrug-resistant cells. , 1988, Biochemical and biophysical research communications.

[29]  Shu Chien,et al.  Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases , 2003 .

[30]  S. Arbuck,et al.  Taxol: the first of the taxanes, an important new class of antitumor agents. , 1992, Seminars in oncology.

[31]  L. Benet,et al.  The effect of water‐soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers , 1996, Clinical pharmacology and therapeutics.

[32]  S. Feng,et al.  In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. , 2006, Biomaterials.

[33]  Earl G. Adams,et al.  Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines , 2004, Cancer Chemotherapy and Pharmacology.

[34]  T. Park,et al.  Biodegradable nanoparticles containing protein-fatty acid complexes for oral delivery of salmon calcitonin. , 2004, Journal of pharmaceutical sciences.

[35]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.

[36]  M. Egorin,et al.  Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice , 2004, Cancer Chemotherapy and Pharmacology.